Compare Sony Group Corp (SONY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs BIO-TECHNE Corp — how do they compare? Sony Group Corp trades at $24.09 (market cap $138.06B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Sony Group Corp is far larger — about 12.1× BIO-TECHNE Corp's market cap, and Sony Group Corp pays the higher dividend (0.67%). Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and BIO-TECHNE Corp for 63 Days on average.
| SONY | TECH | |
|---|---|---|
Market Cap | $138.06B | $11.37B |
Volume | 3,986,731 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $30.26 | $72.61 |
52-Week Low | $19.32 | $43.31 |
Typical Hold Time | 96 Days | 63 Days |
Enterprise Value | $135.96B | $11.40B |
Dividend Yield | 0.67% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $23.95, up 0.42% with neutral technical signals. The company shows strong cash flow generation ($2.32T operating cash flow in 2025) and beat earnings expectations in two of the last three quarters. However, 2026 projections indicate potential challenges with negative net income margin and declining revenue. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations among 16 analysts covering the stock.
Sony presents a mixed investment case with solid entertainment assets and cash flow strength offset by near-term profitability concerns. The stock's reasonable valuation (P/E 19.93, P/S 1.75) and strong analyst support provide upside potential, but investors must monitor execution against 2026 guidance and competitive pressures in entertainment markets.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
